

Long-term protection against herpes zoster (HZ) by the adjuvanted recombinant zoster vaccine (RZV): interim efficacy, immuno and safety results at approximately 10 years after initial vaccination


Ana Strezova, Javier Diez-Domingo, Kamal Al Shawafi, Juan Carlos Tinoco, Meng Shi, Paola Pirrotta, Agnes Mwakingwe-Omari on behalf of the Zoster-049 study group



extension study







IDWeek 2022, 19–23 October 2022, Washington, DC | Funding: GlaxoSmithKline Biologicals SA. Acknowledgments: Medical writing (Maria Cornelia Maior), design and coordination support were provided by Modis c/o GSK. Affiliations, References and Disclosures available via the QR code.

Anti-gE antibody GMC persisted at >5-fold above pre-vaccination

Presenter: Ana Strezova E-mail: ana.x.strezova@gsk.com Poster number: 114

Conclusions







Over the \geq 4-year follow-up in ZOSTER-049, the interim analysis demonstrated 81.6% VE against HZ From 1 month post-second RZV dose up to Y10 post-vaccination, VE against HZ was 89.0%



The humoral and cell-mediated immune responses to RZV remained high until the end of Y4 of ZOSTER-049




RZV safety profile remained clinically acceptable



These results suggest that the clinical benefit of the RZV in adults \geq 50 YOA is sustained up to at least 10 years after vaccination

Median frequency of gE-specific CD4[2+] T cells persisted at >6-fold above pre-vaccination levels up to Y10 after vaccination





Q1/Q3, first/third quartiles. Y5 data for CD4[2+] T cells frequencies not shown because only 3 participants had available results for this analysis. *Pre-vaccination values from all RZV recipients in the CMI subset in ZOE-50/70.



5 participants with a confirmed HZ case reported HZ-related complications:

- 3 participants experienced postherpetic neuralgia
- 2 participants experienced disseminated HZ disease